Chapter 336 - 230: Another Trump Card

Chapter 336: Chapter 230: Another Trump Card

「Xianglin City, Pfizer Research and Development Center」

Xie Bin and Xu Kunlin, as usual, were paying close attention to the latest news about Jin Pharmaceutical Group.

His assistant reported the news they had received in the early hours of the morning:

"President Xie, President Xu, good news. Jin Yihong’s trip to the Southern Country to seek cooperation was a complete failure. Regarding Lou Musaang’s Banzhe Project, none of the experts Jin Yihong met with could offer any help."

"Inside Jin Pharmaceutical Group, complaints are everywhere. Ever since Jia Jun led a team over to Wu’s Pharmaceutical Company, the remaining researchers at the R&D center have been left leaderless on the Banzhe Project. Lou Musaang himself hasn’t appeared at the center for days due to his health issues, and the whole project is in disarray."

"By this estimate, in less than half a month, Jin Pharmaceutical Group will start to crumble from within, without any pressure from the outside."

"Also, Wu’s Pharmaceutical Company has made no research progress during this time either. Jia Jun hasn’t shown his face in a long time. As for that Dr. Wu Ting, he’s just been doing his usual consultations and surgeries, nothing related to pharmaceuticals. We’ve basically confirmed he’s just a tool Jin Yihong is using for a proof-of-concept project to trick the market. He’s no threat."

"From some small clues we’ve gathered, we’ve discovered that Deng Feifei has been trying to raise a significant amount of capital through various means. If our speculation is correct, she and Wu Ting from Wu’s Pharmaceutical Company are probably preparing to follow in her mother’s footsteps by repurchasing company stock to temporarily stabilize market confidence."

"Of course, following this trend, as long as there are no breakthroughs in new drug development, the more money Jin Yihong, Deng Feifei, and Wu Ting pour in, the more they’ll lose."

During this period, Jin Pharmaceutical Group’s stock price had already fallen by a full third!

At a time like this, if Jin Yihong, her daughter, and that reckless brat Wu Ting threw cash into it, the value would just keep shrinking!

Listening to his assistant’s latest report, a greedy look appeared in Xu Kunlin’s eyes.

Xie Bin remained composed, speaking calmly:

"President Xu, Jin Pharmaceutical Group hasn’t hit rock bottom yet. There’s still room for it to fall. We need to wait a little longer."

"Besides, I haven’t played my final card yet."

Xie Bin gave a cold laugh.

"President Xie, you still have another move up your sleeve?"

Xu Kunlin hadn’t expected it. Even at this stage, Xie Bin still had a trump card.

Xie Bin chuckled, looking utterly harmless.

"This time, after Jin Yihong returns to Jin Pharmaceutical Group, the upcoming board meeting will be my final gift to her."

"I’ve already contacted the other shareholders privately. They’re going to make a scene at the board meeting, forcing Jin Yihong to agree to our merger and acquisition plan. The Pfizer Group will inject capital, become the second-largest shareholder, and we’ll jointly develop the Banzhe Project."

"If she remains stubborn, then I’ll offer her a poison pill. I will propose a share acquisition plan at a price above market value, forcing her to make a choice: either she spends the money to buy up those overpriced shares herself, or she can only watch helplessly as we gain a controlling stake and call for a new shareholders’ meeting... Although this plan will cost us much more than the first, it’s still a guaranteed win."

"If Jin Yihong chooses mutual destruction and buys those overpriced shares, she’ll only meet a more miserable end! I will sink Jin Pharmaceutical Group completely and make its stock price utterly collapse. Though, that is the outcome I’d least like to see."

Listening to Xie Bin’s analysis, Xu Kunlin finally saw just how vicious he was.

"This way, Jin Yihong and Jin Pharmaceutical Group will be in the palm of our hand."

"Unless she can produce a new, market-saving drug that can get our Sorafenib pulled from the shelves *while simultaneously* buying up those overpriced shares—she must do both—only then could she rebound from this rock-bottom stock price and rise from the ashes. But, that’s impossible."

Xie Bin wouldn’t let that happen. If he really managed to take down Jin Pharmaceutical Group, only for Jin Yihong to acquire it back and rise from the ashes, wouldn’t that mean he had helped her consolidate her shares and cause her own net worth to skyrocket?

The Banzhe Project was dead. Wu Ting’s team’s concept project couldn’t fool the market and investors a second time. And as for Sorafenib’s toxic side effects, there was no way anyone could discover them in such a short time. What did Jin Yihong have to fight Xie Bin with?

Xie Bin felt completely in control. Once he completed this robbery of Jin Pharmaceutical Group, it would become another classic case of a commercial merger in his career.

As he calculated all the possibilities and details, Xie Bin found himself somewhat admiring the young Wu Ting. To still be so loyal and have the backbone to raise funds through patents and shares to support Jin Pharmaceutical Group at a time like this.

It was just a shame that Wu Ting’s vision was too narrow, his perspective too limited. Pfizer and Xie Bin himself were the commercial titans worthy of his loyalty.

While Xu Kunlin admired Xie Bin, he was also calculating the time. They just needed to hold out a little longer, and then Sorafenib could be recalled.

In such a short time from market launch to recall, it would be impossible to identify Sorafenib’s severe adverse side effects from just a few sporadic, coincidental cases—unless a team was specifically conducting a research project on it.

...

...

「City First Hospital, Emergency Department」

Wu Ting was on duty, partnered with Luo Ming.

Suddenly, a group of people rushed into the emergency room lobby.

They were all wearing professional suits, and on the backs of their clothes was the company name: Weixing Petrochemical.